Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ALZN
- Price
- 2.28
- Stock movement down
- -0.15 (-6.17%)
- Company name
- Alzamend Neuro Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 8.67M
- Ent value
- 4.94M
- Price/Sales
- -
- Price/Book
- 1.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -1.49%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.64%
- 1 year return (CAGR)
- -78.71%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALZN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.98 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.80M |
| EPS (TTM) | -1.74 |
| FCF per share (TTM) | -1.73 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -53.05K |
| Operating income (TTM) | -5.87M |
| Net income (TTM) | -5.88M |
| EPS (TTM) | -1.74 |
| EPS (1y forward) | -2.98 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.45M |
| Net receivables | 0.00 |
| Total current assets | 4.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 5.09M |
| Accounts payable | 717.49K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 717.49K |
| Total liabilities | 717.49K |
| Shareholder's equity | 4.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.65M |
| Capital expenditures (TTM) | 210.00K |
| Free cash flow (TTM) | -5.86M |
| Dividends paid (TTM) | 87.38K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -134.47% |
| Return on Assets | -115.52% |
| Return on Invested Capital | -134.47% |
| Cash Return on Invested Capital | -133.89% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.36 |
| Daily high | 2.53 |
| Daily low | 2.28 |
| Daily Volume | 518K |
| All-time high | 14931.00 |
| 1y analyst estimate | 28.00 |
| Beta | -0.25 |
| EPS (TTM) | -1.74 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ALZN | S&P500 | |
| Current price drop from All-time high | -99.98% | -0.89% |
| Highest price drop | -99.99% | -19.00% |
| Date of highest drop | 31 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -99.96% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
8.67M
Marketcap category
Small-cap
Description
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page